Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

Value of combined detection of four tumor markers in the diagnosis of primary hepatic cancer

Combined determination of serum DCP, GPC3 and HSP70 in diagnosis of AFP-negative primary liver carcinoma

Differential diagnosis of primary hepatic carcinoma by detecting serum alpha-fetoprotein,tumor-associated substances and carcinoembryonic antigen

Diagnostic Value of AFP、AFU、Fer in Primary Liver Cancer

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Clinial Evaluation of Alpha-fetoroptein and Alpha-L-fucosidase in the Diagnosis of Primary Hepatic Cancer

The Value of MRI Combined with AFP, AFP-L3, GP73, and DCP in the Diagnosis of Early Primary Liver Cancer

Comprehensive Evaluation of the Diagnostic Value of the Combined Examination of AFP, AFU and VEGF for Primary Hepatic Carcinoma by Logistic Regression and ROC Curve

Serum Biomarkers AFP, CEA and CA19-9 Combined Detection for Early Diagnosis of Hepatocellular Carcinoma.

Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma.

The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer

Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis

Combination of serum alpha-fetoprotein, PIVKA-Ⅱ and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis

Clinical Utility Of Simultaneous Measurement Of Alpha-Fetoprotein And Des-Gamma-Carboxy Prothrombin For Diagnosis Of Patients With Hepatocellular Carcinoma In China: A Multi-Center Case-Controlled Study Of 1,153 Subjects

Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in china

Combined Detection Of Circulating Tumor Cells, Alpha-Fetoprotein Heterogene-3 And Alpha-Fetoprotein In The Early Diagnosis Of Hcc For The Prediction Of Efficacy, Prognosis, Recurrence After Microwave Ablation

Combined detection of circulating tumor cells, α-fetoprotein heterogene-3 and α-fetoprotein in the early diagnosis of HCC for the prediction of efficacy, prognosis, recurrence after microwave ablation

Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma

Diagnostic Value of 5 Serum Biomarkers for Hepatocellular Carcinoma with Different Epidemiological Backgrounds: A Large-Scale, Retrospective Study

The Value of Serum Glypican-3 Level in Aided Diagnosis of Patients with Primary Hepatocellular Carcinoma

Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer.